29 Sep CP-506 well tolerated at first four dose levels: first clinical results from TUMAGNOSTIC
CP-506, Convert’s hypoxia-activated prodrug, shows no dose-limiting toxicity and confirms tumour-selective activation in the Phase I TUMAGNOSTIC trial....